A phase Ib study of everolimus combined with metformin for patients with advanced cancer

Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers

(2016) Muhammad R. Khawaja et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Metformin and the gastrointestinal tract

(2016) Laura J. McCreight et al.   DIABETOLOGIA

Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes

(2016) Sara Pusceddu et al.   Future Oncology

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

(2016) James C Yao et al.   LANCET

Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma

(2015) Brian M. Slomovitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

(2015) Sil Kordes et al.   LANCET ONCOLOGY

Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells

(2015) Yunshan Wang et al.   ONCOLOGY RESEARCH

Reduced Risk of Lung Cancer With Metformin Therapy in Diabetic Patients: A Systematic Review and Meta-Analysis

(2014) Zhi-Jiang Zhang et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis

(2014) Zheng Wang et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells

(2014) Enrique Rozengurt   Frontiers in Physiology

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

(2013) Helen J. Mackay et al.   CANCER

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

(2013) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Metformin Is Associated With Survival Benefit in Cancer Patients With Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis

(2013) M. Yin et al.   ONCOLOGIST

Effects of Metformin Dose on Cancer Risk Reduction in Patients with Type 2 Diabetes Mellitus: A 6-Year Follow-up Study

(2013) Hsiu-Chen Lin et al.   PHARMACOTHERAPY

Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer

(2012) N. Sadeghi et al.   CLINICAL CANCER RESEARCH

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

(2012) David Neal Franz et al.   LANCET

Clinical Pharmacokinetics of Metformin

(2011) Garry G. Graham et al.   CLINICAL PHARMACOKINETICS

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

(2010) Mahvash Zakikhani et al.   BREAST CANCER RESEARCH AND TREATMENT

PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel

(2010) Yong Zhang et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer

(2010) M. Bodmer et al.   DIABETES CARE

A phase I study of temsirolimus and metformin in advanced solid tumours

(2010) Mary J. MacKenzie et al.   INVESTIGATIONAL NEW DRUGS

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET